Shigeto Ueda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4650361/publications.pdf

Version: 2024-02-01

623734 794594 1,083 21 14 19 citations g-index h-index papers 21 21 21 1726 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Early Therapeutic Prediction Based on Tumor Hemodynamic Response Imaging: Clinical Studies in Breast Cancer with Time-Resolved Diffuse Optical Spectroscopy. Applied Sciences (Switzerland), 2019, 9, 3.	2.5	12
2	Recurrent Angiosarcoma of the Breast Treated with Gemcitabine and Paclitaxel. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2018, 79, 687-691.	0.0	O
3	Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis. Clinical Cancer Research, 2017, 23, 5769-5778.	7.0	70
4	In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. British Journal of Cancer, 2016, 114, 1212-1218.	6.4	82
5	Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using ¹⁸ F-FDG PET/CT. Journal of Nuclear Medicine, 2016, 57, 1189-1195.	5.0	18
6	Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety. Japanese Journal of Clinical Oncology, 2015, 45, 642-649.	1.3	15
7	Phase I study of HER3 targeted antibody patritumab in combination with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC) Journal of Clinical Oncology, 2015, 33, 584-584.	1.6	4
8	Optical Imaging for Monitoring Tumor Oxygenation Response after Initiation of Single-Agent Bevacizumab followed by Cytotoxic Chemotherapy in Breast Cancer Patients. PLoS ONE, 2014, 9, e98715.	2.5	20
9	Clinicopathological and prognostic impact of imaging of breast cancer angiogenesis and hypoxia using diffuse optical spectroscopy. Cancer Science, 2014, 105, 833-839.	3.9	15
10	Near-infrared optical imaging of cancer vascular remodeling after antiangiogenic therapy. Breast Cancer, 2014, 21, 776-779.	2.9	2
11	Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by neoadjuvant chemotherapy in breast cancer patients Journal of Clinical Oncology, 2014, 32, e13503-e13503.	1.6	O
12	Optical imaging of tumor vascularity associated with proliferation and glucose metabolism in early breast cancer: clinical application of total hemoglobin measurements in the breast. BMC Cancer, 2013, 13, 514.	2.6	27
13	Genomic Profiling Shows Increased Glucose Metabolism in Luminal B Breast Cancer. Journal of Breast Cancer, 2013, 16, 342.	1.9	3
14	Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer, 2011, 18, 299-308.	2.9	41
15	Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14626-14631.	7.1	130
16	Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer, 2008, 8, 165.	2.6	104
17	Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer. BMC Cancer, 2008, 8, 384.	2.6	32
18	Clinicopathological and Prognostic Relevance of Uptake Level using 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging (18F-FDG PET/CT) in Primary Breast Cancer. Japanese Journal of Clinical Oncology, 2008, 38, 250-258.	1.3	202

SHIGETO UEDA

#	Article	IF	CITATIONS
19	Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1. Cancer Science, 2006, 97, 597-604.	3.9	38
20	Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Modern Pathology, 2006, 19, 788-796.	5 . 5	52
21	The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness. Pancreas, 2004, 29, e1-e8.	1.1	216